Status:
UNKNOWN
Dornase Alpha for the Treatment of COVID-19
Lead Sponsor:
Acibadem University
Collaborating Sponsors:
The Scientific and Technological Research Council of Turkey
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
In this study, the effectiveness of the Dornase Alpha treatment, which is known to reduce the viscosity of respiratory secretions, will be investigated in new diagnosed and severe COVID-19 patients se...
Detailed Description
Recent studies confirmed the role of immune hyperactivation in the pathogenesis of COVID-19. Immune cells, especially neutrophils, infiltrate pulmonary capillaries that cause acute fibrin deposition a...
Eligibility Criteria
Inclusion
- Being 18 or older
- Approving the Informed Consent Form
- Being diagnosed with COVID-19 with PCR and / or radiological clinical findings
- Hospitalization indication according to Ministry of Health criteria
Exclusion
- Pregnant and / or breastfeeding women.
- Any known allergy to Dornase Alpha
- Being involved in another drug study
- Previously diagnosed with chronic lung disease
Key Trial Info
Start Date :
May 25 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 25 2020
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04432987
Start Date
May 25 2020
End Date
September 25 2020
Last Update
June 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Acıbadem Altunizade Hospital
Istanbul, Turkey (Türkiye), 34662